Racial Differences in S100b Levels in Persons with Schizophrenia.

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• S100b, a calcium-binding protein, is linked to glial cells and melanocytes.
• It acts as a neurotrophic factor at low concentrations and a marker of CNS injury at high concentrations.
• Elevated S100b levels are observed in schizophrenia patients, suggesting potential as a biomarker.

Purpose of the Study:

• To investigate potential ethnic or racial differences in serum S100b levels among individuals with schizophrenia.
• To assess the influence of race on S100b as a potential biomarker in schizophrenia.

Main Methods:

• Serum S100b levels were measured using enzyme-linked immunoassay (ELISA) in 136 schizophrenia participants across two independent studies.
• Data were analyzed comparing S100b levels between African-American and Caucasian subjects.
• Statistical analysis included Mann-Whitney U test to compare groups.

Main Results:

• African-American subjects exhibited significantly higher serum S100b levels (41.9 pg/ml ± 62.2) compared to Caucasian subjects (24.9 pg/ml ± 45.4).
• This difference was consistent across both independent studies.
• No significant differences in S100b levels were found between sexes, nor were correlations observed with demographic or clinical variables.

Conclusions:

• Ethnicity/race is a critical factor influencing serum S100b levels in individuals with schizophrenia.
• Future research and clinical interpretation of S100b must account for racial and ethnic variations.
• S100b's utility as a biomarker in schizophrenia requires careful consideration of these demographic differences.